LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company that recently secured FDA approval for its aceclidine ophthalmic solution VIZZ for presbyopia, has reported preliminary Q4 financial results.
VIZZ, the first and only FDA-approved acetylcholine-based eye drop for the treatment of presbyopia, was approved by the FDA in August 2025.
Notably, since the launch of VIZZ last October and its broad availability since mid-November, more than 20,000 prescriptions were filled in the fourth quarter of 2025. In addition, over 6,500 unique Eye Care Professionals or ECPs have prescribed VIZZ, with more than 55% prescribing multiple times in the fourth quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.